Use of anticoagulants in elderly patients

Thrombosis Research

Volumn 129, Issue 2, 2012, Pages 107-115

  Bauersachs, Rupert M ^a  

^a KLINIKUM DARMSTADT   (Germany)

Author keywords

Anticoagulation; Apixaban; Dabigatran etexilate; Elderly patients; Rivaroxaban; Thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; DABIGATRAN ETEXILATE; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; COMORBIDITY; ELDERLY CARE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; STROKE; SURGICAL PATIENT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; HEMORRHAGE; HUMANS; THROMBOEMBOLISM;

EID: 84855905401     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.09.013     Document Type: Review

References (86)

1. F.A. Spencer, J.M. Gore, D. Lessard, C. Emery, L. Pacifico, and G. Reed Venous thromboembolism in the elderly. A community-based perspective Thromb Haemost 100 2008 780 788
2. M.J. Engbers, A. van Hylckama Vlieg, and F.R. Rosendaal Venous thrombosis in the elderly: incidence, risk factors and risk groups J Thromb Haemost 8 2010 2105 2112
3. I.A. Naess, S.C. Christiansen, P. Romundstad, S.C. Cannegieter, F.R. Rosendaal, and J. Hammerstrom Incidence and mortality of venous thrombosis: a population-based study J Thromb Haemost 5 2007 692 699 (Pubitemid 46563566)
4. R. Alikhan, A.T. Cohen, S. Combe, M.M. Samama, L. Desjardins, and A. Eldor Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study Blood Coagul Fibrinolysis 14 2003 341 346 (Pubitemid 36688187)
5. S. Weill-Engerer, S. Meaume, A. Lahlou, F. Piette, O. Saint-Jean, and A. Sachet Risk factors for deep vein thrombosis in inpatients aged 65 and older: a case-control multicenter study J Am Geriatr Soc 52 2004 1299 1304 (Pubitemid 39038202)
6. L. López-Jiménez, M. Montero, J.A. González-Fajardo, J.I. Arcelus, C. Suárez, and J.L. Lobo Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE) Haematologica 91 2006 1046 1051 (Pubitemid 44204770)
7. S. Laporte, P. Mismetti, H. Decousus, F. Uresandi, R. Otero, and J.L. Lobo Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry Circulation 117 2008 1711 1716 (Pubitemid 351482603)
8. S. Goodacre, A.J. Sutton, and F.C. Sampson Meta-analysis: The value of clinical assessment in the diagnosis of deep venous thrombosis Ann Intern Med 143 2005 129 139
9. P.L. Harper, E. Theakston, J. Ahmed, and P. Ockelford D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly Intern Med J 37 2007 607 613 (Pubitemid 47262895)
10. A.S. Go, E.M. Hylek, K.A. Phillips, Y. Chang, L.E. Henault, and J.V. Selby Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study JAMA 285 2001 2370 2375 (Pubitemid 32424106)
11. D.E. Singer, G.W. Albers, J.E. Dalen, M.C. Fang, A.S. Go, and J.L. Halperin Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 546S 592S (Pubitemid 351892972)
12. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study Arch Intern Med 147 1987 1561 1564 (Pubitemid 17138836)
13. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
14. W.H. Geerts, D. Bergqvist, G.F. Pineo, J.A. Heit, C.M. Samama, and M.R. Lassen Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 381S 453S (Pubitemid 351894916)
15. C. Kearon, S.R. Kahn, G. Agnelli, S. Goldhaber, G.E. Raskob, and A.J. Comerota Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 454S 545S (Pubitemid 351892971)
16. R.J. Glassock, and C. Winearls Ageing and the glomerular filtration rate: truths and consequences Trans Am Clin Climatol Assoc 120 2009 419 428
17. R.H. White, M.A. McBurnie, T. Manolio, C.D. Furberg, J.M. Gardin, and S.J. Kittner Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort Am J Med 106 1999 165 171 (Pubitemid 29115956)
18. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 160S 198S (Pubitemid 351892967)
19. Anon The use of oral anticoagulants (warfarin) in older people. American Geriatrics Society guideline J Am Geriatr Soc 50 2002 1439 1445
20. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, and S. Ernst Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
21. V. Fuster, L.E. Rydén, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society J Am Coll Cardiol 48 2006 e149 e246
22. A. Leizorovicz, A.T. Cohen, A.G.G. Turpie, C.G. Olsson, P.T. Vaitkus, and S.Z. Goldhaber Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Circulation 110 2004 874 879 (Pubitemid 39096017)
23. R.D. Hull, S.M. Schellong, V.F. Tapson, M. Monreal, M.M. Samama, and P. Nicol Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial Ann Intern Med 153 2010 8 18
24. F.X. Kleber, C. Witt, G. Vogel, K. Koppenhagen, U. Schomaker, and C.W. Flosbach Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease Am Heart J 145 2003 614 621 (Pubitemid 36403489)
25. A.T. Cohen, B.L. Davidson, A.S. Gallus, M.R. Lassen, M.H. Prins, and W. Tomkowski Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial BMJ 332 2006 325 329
26. M. Monreal, and L. López-Jiménez Pulmonary embolism in patients over 90 years of age Curr Opin Pulm Med 16 2010 432 436
27. N.R. Campbell, R.D. Hull, R. Brant, D.B. Hogan, G.F. Pineo, and G.E. Raskob Aging and heparin-related bleeding Arch Intern Med 156 1996 857 860 (Pubitemid 26119813)
28. S.A. Spinler, and C.M. Evans Update in unfractionated heparin, low-molecular-weight heparins, and heparinoids in the elderly (age ≥ 65 years) J Thromb Thrombolysis 9 2000 117
29. J. Hirsh, K.A. Bauer, M.B. Donati, M. Gould, M.M. Samama, and J.I. Weitz Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition) Chest 133 2008 141S 159S (Pubitemid 351892966)
30. P. Mismetti, S. Laporte-Simitsidis, C. Navarro, P. Sie, P. dAzemar, and J. Necciari Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin) Thromb Haemost 79 1998 1162 1165 (Pubitemid 28297165)
31. Glaxo Group Ltd Arixtra Summary of Product Characteristics Available at: http://emc.medicines.org.uk/medicine/15123 2010
32. R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis Ann Intern Med 131 1999 492 501 (Pubitemid 29482392)
33. C. van Walraven, R.G. Hart, D.E. Singer, A. Laupacis, S. Connolly, and P. Petersen Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis JAMA 288 2002 2441 2448 (Pubitemid 35340540)
34. F.J. van der Meer, F.R. Rosendaal, J.P. Vandenbroucke, and E. Briët Bleeding complications in oral anticoagulant therapy. An analysis of risk factors Arch Intern Med 153 1993 1557 1562 (Pubitemid 23205854)
35. V. Pengo, C. Legnani, F. Noventa, and G. Palareti Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study Thromb Haemost 85 2001 418 422 (Pubitemid 32233011)
36. V. Pengo, U. Cucchini, G. Denas, B.L. Davidson, F. Marzot, and S.P. Jose Lower versus standard intensity oral anticoagulant therapy (OAT) in elderly warfarin-experienced patients with non-valvular atrial fibrillation Thromb Haemost 103 2010 442 449
37. M.C. Fang, Y. Chang, E.M. Hylek, J. Rosand, S.M. Greenberg, and A.S. Go Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation Ann Intern Med 141 2004 745 752
38. E.M. Hylek, C. Evans-Molina, C. Shea, L.E. Henault, and S. Regan Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation Circulation 115 2007 2689 2696 (Pubitemid 46842784)
39. M. Marcucci, A. Iorio, A. Nobili, M. Tettamanti, L. Pasina, and A. Marengoni Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards Eur J Intern Med 21 2010 516 523
40. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects Eur J Clin Pharmacol 61 2005 873 880 (Pubitemid 41803696)
41. D. Kubitza, M. Becka, A. Roth, and W. Mueck Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects Curr Med Res Opin 24 2008 2757 2765
42. ® Summary of Product Characteristics Available at: http://www.medicines.org.uk/emc/document.aspx? documentId=21265 2011
43. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf The effect of extreme age, and gender, on the pharmacology and tolerability of rivaroxaban - an oral, direct Factor Xa inhibitor Blood (ASH Annual Meeting Abstracts) 108 2006 905
44. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - has no clinically relevant interaction with naproxen Br J Clin Pharmacol 63 2007 469 476 (Pubitemid 46426627)
45. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct Factor Xa inhibitor - are not affected by aspirin J Clin Pharmacol 46 2006 981 990 (Pubitemid 44215062)
46. D. Kubitza, M. Becka, W. Mueck, and M. Zuehlsdorf Co-administration of rivaroxaban - a novel, oral, direct Factor Xa inhibitor - and clopidogrel in healthy subjects Eur Heart J 28 Suppl 1 2007:189 (P1272)
47. D. Kubitza, M. Becka, M. Zuehlsdorf, and W. Mueck No interaction between the novel, oral direct Factor Xa inhibitor BAY 59-7939 and digoxin J Clin Pharmacol 46 2006 702 (11)
48. D. Kubitza, W. Mueck, and M. Becka No interaction between rivaroxaban - a novel, oral, direct factor Xa inhibitor - and atorvastatin Pathophysiol Haemost Thromb 36 Suppl 1 2008 A40 (P062)
49. C. Frost, Z. Yu, S. Nepal, R. Mosqueda-Garcia, and A. Shenker Apixaban, an oral direct Factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy volunteers J Thromb Haemost 5 Suppl 1 2007 (P-M-665)
50. C.E. Frost, S. Nepal, Y. Barrett, and F. LaCreta Effects of age and gender on the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of apixaban J Thromb Haemost 7 Suppl s2 2009 455 (PP-MO-407)
51. N. Raghavan, C.E. Frost, Z. Yu, K. He, H. Zhang, and W.G. Humphreys Apixaban metabolism and pharmacokinetics after oral administration to humans Drug Metab Dispos 37 2009 74 81
52. Bristol-Myers Squibb, and Pfizer EEIG Eliquis Summary of Product Characteristics Available at: http://www.eliquis.com/PDF/ ELIQUIS%20%AE%20(apixaban)%20SmPC.pdf 2011
53. J. Carreiro, and J. Ansell Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict Expert Opin Investig Drugs 17 2008 1937 1945
54. J. Stangier, K. Rathgen, H. Stähle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303 (Pubitemid 47283865)
55. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 2008 285 295 (Pubitemid 351508116)
56. J. Stangier, H. Stähle, K. Rathgen, and R. Fuhr Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects Clin Pharmacokinet 47 2008 47 59 (Pubitemid 350260888)
57. J. Stangier, and A. Clemens Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor Clin Appl Thromb Hemost 15 Suppl 1 2009 9S 16S
58. J. Stangier, H. Stähle, K. Rathgen, K. Reseski, and T. Konicke No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin J Thromb Haemost 5 Suppl 2 2007 (P-W-672)
59. J. Stangier, H. Stähle, K. Rathgen, K. Reseski, and T. Kornicke Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug J Thromb Haemost 5 Suppl 2 2007 (P-T-677)
60. J. Stangier, K. Rathgen, H. Stähle, K. Reseski, T. Kornicke, and W. Roth Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics Am J Cardiovasc Drugs 9 2009 59 68
61. B.I. Eriksson, L.C. Borris, R.J. Friedman, S. Haas, M.V. Huisman, and A.K. Kakkar Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty N Engl J Med 358 2008 2765 2775 (Pubitemid 351930851)
62. A.K. Kakkar, B. Brenner, O.E. Dahl, B.I. Eriksson, P. Mouret, and J. Muntz Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial Lancet 372 2008 31 39
63. M.R. Lassen, W. Ageno, L.C. Borris, J.R. Lieberman, N. Rosencher, and T.J. Bandel Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty N Engl J Med 358 2008 2776 2786 (Pubitemid 351930852)
64. A.G.G. Turpie, M.R. Lassen, B.L. Davidson, K.A. Bauer, M. Gent, and L.M. Kwong Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Lancet 373 2009 1673 1680
65. A.G.G. Turpie, M.R. Lassen, B.I. Eriksson, M. Gent, S.D. Berkowitz, and F. Misselwitz Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies Thromb Haemost 105 2011 444 453
66. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and R.J. Portman Apixaban or enoxaparin for thromboprophylaxis after knee replacement N Engl J Med 361 2009 594 604
67. M.R. Lassen, G.E. Raskob, A. Gallus, G. Pineo, D. Chen, and P. Hornick Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Lancet 375 2010 807 815
68. M.R. Lassen, A. Gallus, G.E. Raskob, G. Pineo, D. Chen, and L.M. Ramirez Apixaban versus enoxaparin for thromboprophylaxis after hip replacement N Engl J Med 363 2010 2487 2498
69. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial Lancet 370 2007 949 956 (Pubitemid 47393577)
70. B.I. Eriksson, O.E. Dahl, N. Rosencher, A.A. Kurth, C.N. van Dijk, and S.P. Frostick Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial J Thromb Haemost 5 2007 2178 2185 (Pubitemid 47617868)
71. The RE-MOBILIZE Writing Committee Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery J Arthroplasty 24 2009 1 9
72. A.T. Cohen, T.E. Spiro, H.R. Büller, L. Haskell, D. Hu, and R. Hull Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol J Thromb Thrombolysis 31 2011 407 416
73. A.T. Cohen, T.E. Spiro, H.R. Büller, L. Haskell, D. Hu, and R. Hull Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients American College of Cardiology Congress 60th Annual Scientific Session 2011 Available at: http://my. americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/documents/ downloadable/ucm-425442.pdf
74. The EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
75. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 2009 2342 2352
76. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
77. R.D. Lopes, J.H. Alexander, S.M. Al-Khatib, J. Ansell, R. Diaz, and J.D. Easton Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale Am Heart J 159 2010 331 339
78. J.W. Eikelboom, M. ODonnell, S. Yusuf, R. Diaz, G. Flaker, and R. Hart Rationale and design of AVERROES: Apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment Am Heart J 159 2010 348 353
79. S.J. Connolly, J. Eikelboom, G. Flaker, S. Kaatz, A. Avezum, and L. Piegas AVERROES: apixaban versus acetylsalicylic acid (ASA) to prevent strokes European Society of Cardiology congress 2010 Available at: http://www.escardio. org/congresses/esc-2010/congress-reports/Documents/Tuesday/AVERROES-discussant- slides-Connolly.pdf
80. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, and A. Parekh Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
81. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, P.A. Reilly, and L. Wallentin Newly identified events in the RE-LY trial N Engl J Med 363 2010 1875 1876
82. B.F. Gage Can we rely on RE-LY? N Engl J Med 361 2009 1200 1202
83. J.W. Eikelboom, L. Wallentin, S.J. Connolly, M. Ezekowitz, J.S. Healey, and J. Oldgren Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 2011 2363 2372
84. D. Kubitza, M. Becka, W. Mueck, A. Halabi, H. Maatouk, and N. Klause Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban - an oral, direct Factor Xa inhibitor Br J Clin Pharmacol 70 2010 703 712
85. M. Legrand, J. Mateo, A. Aribaud, S. Ginisty, P. Eftekhari, and P.T.B. Huy The use of dabigatran in elderly patients Arch Intern Med 171 2011 1285 1286
86. P.L. Gross, and J.I. Weitz New anticoagulants for treatment of venous thromboembolism Arterioscler Thromb Vasc Biol 28 2008 380 386